Gossamer Bio
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
3115 Merryfield Row Ste 120, San Diego, ...Phone Number
(858) 684-1300Website
www.gossamerbio.comRevenue
$53.3 MillionStock Symbol
GOSSIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Gossamer Bio
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for pulmonary hypertension. Its lead product, seralutinib, is being developed for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, addressing significant unmet medical needs.Explore more
Gossamer Bio Org Chart
LF
Executive Director, Project Management
JW
Senior Director, CMC Project Management
NS
Global Director, Congress Strategy & Executio...
RP
Associate Director, CSV
IG
Director, Translational Medicine Operations
RC
Director
BP
Director, Clinical Quality Assurance
IL
Associate Director, Regulatory & Project Mana...
JS
Associate Director, Translational Medicine Op...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Gossamer Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Gossamer Bio
Click to see if Gossamer Bio had a recent Job posting/layoffs
Product Launch: Get notified when Gossamer Bio launches new products
Check if Gossamer Bio has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Gossamer Bio recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Gossamer Bio has new funding data
Check out if Gossamer Bio is spiking on competitors!
Gossamer Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Gossamer Bio as Masked Content
Find 3 more new buyers
Compare Similar Companies to Gossamer Bio
Compare insights from companies similar to Gossamer Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Gossamer Bio financials insights
Gather financial insights about Gossamer Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Share Placement
$120M
2023
Share Placement
$212M
2026
Stock/Share Issuance
$25M
Gossamer Bio Tech Stack
A closer look at the technologies used by Gossamer Bio
Most Recent Scoops
Person-Based
Earnings, Finance
Person-Based
Product Development, Pharmaceuticals
Person-Based
Corporate Strategy
Person-Based
Acquisitions
Person-Based
Acquisitions, Finance, Financing & Debt
Gossamer Bio News & Media
Gossamer Bio Secures Up to $250 Million Private Placement to Fund Seralutinib Through ...
Gossamer Bio has structured the financing around key seralutinib regulatory milestones, with $150 million committed and another $100 million potentially available if the pulmonary arterial hypertension drug receives FDA approval. Key Investor TakeawaysGossamer Bio (NASDAQ:GOSS) has secured up to $250 million through a structured private placement tied to seralutinib’s regulatory progress.Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm
NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Gossamer Bio, Inc. (NASDAQ: GOSS) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Gossamer Bio...Gossamer Bio shares jump after FDA update and seralutinib rights return
Gossamer Bio Inc. (NASDAQ:GOSS) shares surged 25% on Monday after the biotechnology company provided a positive regulatory update on its lead drug candidate, seralutinib, and announced it had regained full global rights to the therapy.Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
New class action for Gossamer (GOSS) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 6/1/2026
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Gossamer Bio
Sign Up For FreeTo access detailed company insights
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for pulmonary hypertension. Its lead product, seralutinib, is being developed for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, addressing significant unmet medical n... Read More
